• +1-646-491-9876
    • +91-20-67278686

    Search

    Dental Pain-Pipeline Review H1 2017

    Dental Pain-Pipeline Review H1 2017

    • Report Code ID: RW0001834381
    • Category Pharmaceuticals
    • No. of Pages 35
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Dental Pain - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Dental Pain - Pipeline Review, H1 2017, provides an overview of the Dental Pain (Central Nervous System) pipeline landscape.

    A pain in the tooth is called dental pain. This can be caused by tooth decay, damaged filling, tooth fracture, etc. Symptoms of a toothache may include: tooth pain that may be sharp, throbbing, or constant. In some people, pain results only when pressure is applied to the tooth. Swelling around the tooth, fever or headache and foul-tasting drainage from the infected tooth occurs. Treatment for a toothache depends on the cause.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Dental Pain - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Dental Pain (Central Nervous System) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Dental Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dental Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 1 and 1 respectively.

    Dental Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Dental Pain (Central Nervous System) .
    - The pipeline guide reviews pipeline therapeutics for Dental Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Dental Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Dental Pain (Central Nervous System) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Dental Pain (Central Nervous System)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Dental Pain (Central Nervous System) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Dental Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Dental Pain - Overview
    Dental Pain - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Dental Pain - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Dental Pain - Companies Involved in Therapeutics Development
    Boehringer Ingelheim GmbH
    Laboratorios Del Dr Esteve SA
    Pacira Pharmaceuticals Inc
    Teva Pharmaceutical Industries Ltd
    Dental Pain - Drug Profiles
    (celecoxib + tramadol hydrochloride) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    A-100 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AFAP-3 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BI-1026706 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    bupivacaine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    funapide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Dental Pain - Dormant Projects
    Dental Pain - Discontinued Products
    Dental Pain - Product Development Milestones
    Featured News & Press Releases
    Jun 21, 2012: Iroko Pharma Announces Phase III Study Results Of Diclofenac
    Nov 04, 2011: Phase II Results For Nano-formulated NSAIDs Under Development At Iroko Pharmaceuticals To Be Reported At ACR Meeting
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Dental Pain, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Dental Pain - Pipeline by Boehringer Ingelheim GmbH, H1 2017
    Dental Pain - Pipeline by Laboratorios Del Dr Esteve SA, H1 2017
    Dental Pain - Pipeline by Pacira Pharmaceuticals Inc, H1 2017
    Dental Pain - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017
    Dental Pain - Dormant Projects, H1 2017
    Dental Pain - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Dental Pain - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Dental Pain, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Boehringer Ingelheim GmbH
    Laboratorios Del Dr Esteve SA
    Pacira Pharmaceuticals Inc
    Teva Pharmaceutical Industries Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//dental-pain-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//dental-pain-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//dental-pain-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments